Anne Zimmerman, editor-in-chief of the Columbia University online journal, <a href=" target="_blank">Voices in Bioethics ...

Ironwood Pharmaceuticals is a smaller company than it was in 2016, when Life Science Leader wrote a feature article about its ...

Longer time horizons and therapeutic area expertise make philanthropy venture capital an attractive option for ...

Job rotations provide an opportunity for promising, high-potential employees to grow and learn new parts of the business.

Part two of a two-part series that identifies current uses of AI in drug discovery and development and assesses whether AI ...

Spinogenix is using small molecule drugs to regenerate synapses in patients with ALS, Alzheimer's disease, schizophrenia, ...

This presentation highlights key pharmaceutical launches anticipated in 2025, emphasizing their potential to address unmet needs across various medical fields. The document covers new developments in ...

Inozyme's CEO and chairman Douglas Treco shares his thoughts about the rousing success of the Orphan Drug Act, but cautions rare disease drug developers against sky high and inaccessible drug pricing ...

In the rapidly evolving landscape of pharmaceutical development, AI promises to revolutionize the entire drug discovery and development process, impacting target discovery, clinical trial design, site ...